Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes

PURPOSE. We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative agerelated macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice. METHODS. Index visit characteristics, such as lesion type and size, visual acu...

Full description

Bibliographic Details
Main Authors: Gillies, M., Walton, R., Simpson, J., Arnold, J., Guymer, R., McAllister, I., Hunyor, A., Essex, R., Morlet, Nigel, Barthelmes, D.
Format: Journal Article
Published: 2013
Online Access:http://hdl.handle.net/20.500.11937/33849
_version_ 1848754061043564544
author Gillies, M.
Walton, R.
Simpson, J.
Arnold, J.
Guymer, R.
McAllister, I.
Hunyor, A.
Essex, R.
Morlet, Nigel
Barthelmes, D.
author_facet Gillies, M.
Walton, R.
Simpson, J.
Arnold, J.
Guymer, R.
McAllister, I.
Hunyor, A.
Essex, R.
Morlet, Nigel
Barthelmes, D.
author_sort Gillies, M.
building Curtin Institutional Repository
collection Online Access
description PURPOSE. We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative agerelated macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice. METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression. RESULTS. Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections. CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice. © 2013 Association for Research in Vision and Ophthalmology, Inc.
first_indexed 2025-11-14T08:34:25Z
format Journal Article
id curtin-20.500.11937-33849
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:34:25Z
publishDate 2013
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-338492023-02-22T06:24:20Z Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes Gillies, M. Walton, R. Simpson, J. Arnold, J. Guymer, R. McAllister, I. Hunyor, A. Essex, R. Morlet, Nigel Barthelmes, D. PURPOSE. We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative agerelated macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice. METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression. RESULTS. Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections. CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice. © 2013 Association for Research in Vision and Ophthalmology, Inc. 2013 Journal Article http://hdl.handle.net/20.500.11937/33849 10.1167/iovs.13-11993 unknown
spellingShingle Gillies, M.
Walton, R.
Simpson, J.
Arnold, J.
Guymer, R.
McAllister, I.
Hunyor, A.
Essex, R.
Morlet, Nigel
Barthelmes, D.
Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes
title Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes
title_full Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes
title_fullStr Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes
title_full_unstemmed Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes
title_short Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes
title_sort prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes
url http://hdl.handle.net/20.500.11937/33849